Cipro - acinetobacter baumannii blood isolate

Body 2. (click set to zoom) Portion of antimicrobials susceptible to A. baumannii, 1989-1998.
For imipenem-cilastatin, data are from August 1990-1998.
Ami = amikacin; A-S = ampicillin-sulbactam; Ceftaz = ceftazidime; Cipro = ciprofloxacin; I-C = imipenem-sulbactam; Pip = piperacillin.
Presumed eradication occurred in 97% of patients receiving ampicillin-sulbactam and 100% of those treated with imipenem-cilastatin.
One patient role treated with ampicillin-sulbactam did not have repeat cultures and died before medical building firing off.
Concomitant organisms included a collection of gram-negative and gram-positive organisms, as well as Candida sp (Figure 3).
The respiratory geographic area was the site most frequently concomitantly infected with A. baumannii (ampicillin-sulbactam 47%, imipenem-cilastatin 72%).
Other adjective polish sites were wounds, urine, catheter tips, and eyes.
Physique 3. (click mental image to zoom) Frequency/patient of concomitant organisms.
Imipenem-cilastatin dosages ranged from 2-4 g/day intravenously or the renal-dosed equivalent weight.
Bill percent of patients received 500 mg intravenously every 6 hour, 44% received 1 g intravenously every 6 distance, and 1 patient role (6%) received 500 mg intravenously every 8 distance.
Ampicillin-sulbactam dosages ranged from 1 g ampicillin-0.5 g sulbactam intravenously every 6 distance (20%) to 2 g ampicillin-1 g sulbactam intravenously every 6 time period (80%), or its renal-dosed atomic weight.
This is a part of article Cipro - acinetobacter baumannii blood isolate Taken from "Cipro Antibiotic" Information Blog